US 12,358,976 B2
Methods for increasing serum concentration of phosphorous and/or 1,25-hydroxy vitamin d
Emil D. Kakkis, Novato, CA (US); Javier San Martin, Novato, CA (US); and Tomohiro Sudo, Tokyo (JP)
Assigned to Ultragenyx Pharmaceutical Inc., Novato, CA (US); and Kyowa Kirin Co., Ltd., Tokyo (JP)
Filed by Ultragenyx Pharmaceutical Inc., Novato, CA (US); and Kyowa Kirin Co., Ltd., Tokyo (JP)
Filed on Aug. 7, 2023, as Appl. No. 18/366,447.
Application 18/366,447 is a continuation of application No. 17/525,738, filed on Nov. 12, 2021, granted, now 11,771,748.
Application 17/525,738 is a continuation of application No. 16/831,179, filed on Mar. 26, 2020, granted, now 11,202,822, issued on Dec. 21, 2021.
Application 16/831,179 is a continuation of application No. 14/725,320, filed on May 29, 2015, granted, now 10,639,360, issued on May 5, 2020.
Claims priority of provisional application 62/009,474, filed on Jun. 9, 2014.
Prior Publication US 2024/0115683 A1, Apr. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/22 (2006.01)
CPC C07K 16/22 (2013.01) [A61K 39/001132 (2018.08); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/90 (2013.01)] 20 Claims
 
1. A method of increasing serum phosphorus levels in a subject having a hypophosphatemic disorder, said method comprising administering to the subject an effective amount of an anti-FGF23 antibody, wherein the anti-FGF23 antibody is administered about every two weeks, and wherein the anti-FGF23 antibody comprises the CDR sequences of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.